amycretin Novo Nordisk, which makes Wegovy and Ozempic, is testing this experimental, unimolecular drug to target two hormone pathways, GLP-1 and amylin, a hormone that helps control hunger
Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor which reduces appetite and slows gastric emptying [6] [7] GIP (glucose-dependent insulinotropic polypeptide) receptor which enhances insulin secretion and may improve fat metabolism [9] [10] Glucagon receptor which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
Adipose-derived inflammation contributes to systemic low-grade inflammation through the release of cytokines such as TNF-, IL-6, and IL17, which can exacerbate keratinocyte activation and immune dysregulation in psoriatic skin
Precision is Key: Use sterile tools and measure carefully to get the correct ratio for your study
Probiotics Supporting Gut Health and Digestive Comfort Why it matters: GLP-1 medications alter gut motility, which can disrupt the microbiome and trigger symptoms like bloating, diarrhea, and digestive discomfort, particularly in the early weeks of treatment
Current U.S
.webp)
